Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel S Merseburger

Showing results (121-130 of 323) with videos related to

Pageof 33
Sort By:
World Journal of Urology|July 3, 2008
Loss of galectin-3 expression correlates with clear cell renal carcinoma progression and reduced survivalAxel S Merseburger, Mario W Kramer, Jörg Hennenlotter, et al.
Aktuelle Urologie|April 9, 2020
[Early- vs. late-onset treatment using abiraterone acetate plus prednisone in chemo-naïve, asymptomatic or mildly symptomatic patients with metastatic CRPC after androgen deprivation therapy]Axel S Merseburger, Christoph Rüssel, Hanjo Belz, et al.
Advances in Therapy|November 28, 2016
True Incidence of Gleason 6 Pathology in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)Alena Böker, Markus A Kuczyk, Mario W Kramer, et al.
European Urology|June 15, 2013
EAU guidelines on robotic and single-site surgery in urologyAxel S Merseburger, Thomas R W Herrmann, Shahrokh F Shariat, et al.
Scientific Reports|March 29, 2018
Urinary CE-MS peptide marker pattern for detection of solid tumorsIwona Belczacka, Agnieszka Latosinska, Justyna Siwy, et al.
World Journal of Urology|March 8, 2022
The utility of infographics and videographics in the modern era: maximising social media impact for research disseminationKhi Yung Fong, Ee Jean Lim, Vishesh Gauhar, et al.
Aktuelle Urologie|June 25, 2024
[Therapy sequences and duration in mCRPC: a retrospective review of the Lübeck mCRPC cohort]Marten Müller, Semih Sarcan, Anne Offermann, et al.
Der Urologe. Ausg. A|June 22, 2021
[Diagnostic markers in urology]Marie C Hupe, Marie C Hempel, Severin Rodler, et al.
Anticancer Research|December 13, 2005
Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experienceAngela Boehmer, Aristotelis G Anastasiadis, Susan Feyerabend, et al.
Cancer Treatment and Research Communications|July 4, 2020
Antibody selection influences the detection of AR-V7 in primary prostate cancerAdam Kaczorowski, Xin Chen, Esther Herpel, et al.
Pageof 33

Showing results (121-130 of 323) with videos related to

Sort By:
Pageof 33
World Journal of Urology|July 3, 2008
Loss of galectin-3 expression correlates with clear cell renal carcinoma progression and reduced survivalAxel S Merseburger, Mario W Kramer, Jörg Hennenlotter, et al.
Aktuelle Urologie|April 9, 2020
[Early- vs. late-onset treatment using abiraterone acetate plus prednisone in chemo-naïve, asymptomatic or mildly symptomatic patients with metastatic CRPC after androgen deprivation therapy]Axel S Merseburger, Christoph Rüssel, Hanjo Belz, et al.
Advances in Therapy|November 28, 2016
True Incidence of Gleason 6 Pathology in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)Alena Böker, Markus A Kuczyk, Mario W Kramer, et al.
European Urology|June 15, 2013
EAU guidelines on robotic and single-site surgery in urologyAxel S Merseburger, Thomas R W Herrmann, Shahrokh F Shariat, et al.
Scientific Reports|March 29, 2018
Urinary CE-MS peptide marker pattern for detection of solid tumorsIwona Belczacka, Agnieszka Latosinska, Justyna Siwy, et al.
World Journal of Urology|March 8, 2022
The utility of infographics and videographics in the modern era: maximising social media impact for research disseminationKhi Yung Fong, Ee Jean Lim, Vishesh Gauhar, et al.
Aktuelle Urologie|June 25, 2024
[Therapy sequences and duration in mCRPC: a retrospective review of the Lübeck mCRPC cohort]Marten Müller, Semih Sarcan, Anne Offermann, et al.
Der Urologe. Ausg. A|June 22, 2021
[Diagnostic markers in urology]Marie C Hupe, Marie C Hempel, Severin Rodler, et al.
Anticancer Research|December 13, 2005
Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experienceAngela Boehmer, Aristotelis G Anastasiadis, Susan Feyerabend, et al.
Cancer Treatment and Research Communications|July 4, 2020
Antibody selection influences the detection of AR-V7 in primary prostate cancerAdam Kaczorowski, Xin Chen, Esther Herpel, et al.
Pageof 33